As communicated in a press release in March 2023, Ortivus entered into an agreement with the Estonian Health Insurance Fund, Tervisekassa, under which Ortivus, together with Telia Eesti AS, was to develop and deliver a SaaS-based solution including MobiMed ePR to Estonia’s national ambulance fleet. The contract covered a period of five years with an estimated order value of approximately 26 MSEK.

Due to the complexity of the project and delays in the timeline, the involved parties have, after joint discussions, mutually agreed to terminate the collaboration. As a result of the termination, Ortivus will reimburse Telia Eesti with an amount of EUR 375,000 (SEK 4,121 thousand) at the end of Q3 2025, representing part of the fees previously invoiced by Ortivus during the course of the project. As a consequence, Ortivus’ result for Q2 2025 will be impacted by SEK 5,121 thousand, which also includes previously recognized profit of approximately SEK 1 million.

“For Ortivus, the collaboration with Tervisekassa and Telia Eesti was a valuable opportunity to support the development of ambulance services in Estonia. The decision to terminate the project was taken jointly, as it became clear that the complexity of the initiative made it unlikely to meet expectations. Overall, we value the constructive cooperation that has taken place throughout the entire process,” said Gustaf Nordenhök, CEO of Ortivus AB.

Contacts

For further information, please contact

Gustaf Nordenhök, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process. 

Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.

Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.

Read more about our solutions at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-09 08:00 CEST.

Attachments

Ortivus reaches agreement on the termination of the project with the Estonian Health Insurance Fund

Läs mer på MFN